Protara Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Protara Therapeutics, Inc. (TARA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $314.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2023-05-04
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-03-31 was $314.00K, a 0.00% change year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-09-30 was $287.00K, a 78.04% decline year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-06-30 was $390.00K, a 71.32% decline year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-03-31 was $314.00K, a 75.90% decline year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.27M, a 71.84% decline from fiscal 2021.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $4.52M, a 33.37% increase from fiscal 2020.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $3.39M, a 982.75% increase from fiscal 2019.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $313.00K, a 90.87% decline from fiscal 2018.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-03-31 | $314.00K 10-Q · filed 2023-05-04 | |||||
| 2022-12-31 | $1.27M 10-K · filed 2023-03-08 | |||||
| 2022-09-30 | $287.00K 10-Q · filed 2022-11-03 | $677.00K derived: sum of 2 quarters · filed 2022-11-03 | $991.00K derived: sum of 3 quarters · filed 2023-05-04 | |||
| 2022-06-30 | $390.00K 10-Q · filed 2022-11-03 | $704.00K derived: sum of 2 quarters · filed 2023-05-04 | ||||
| 2022-03-31 | $314.00K 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | $4.52M 10-K · filed 2023-03-08 | |||||
| 2021-09-30 | $1.31M 10-Q · filed 2022-11-03 | $2.67M derived: sum of 2 quarters · filed 2022-11-03 | $3.97M derived: sum of 3 quarters · filed 2022-11-03 | $5.00M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $1.36M 10-Q · filed 2022-11-03 | $2.66M derived: sum of 2 quarters · filed 2022-11-03 | $3.70M derived: sum of 3 quarters · filed 2022-11-03 | $5.17M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $1.30M 10-Q · filed 2022-11-03 | $2.34M derived: sum of 2 quarters · filed 2022-11-03 | $3.81M derived: sum of 3 quarters · filed 2022-11-03 | $4.32M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2020-12-31 | $1.03M derived: 10-K 12 month − 3 quarters · filed 2021-03-11 | $2.51M derived: sum of 2 quarters · filed 2021-03-11 | $3.02M derived: sum of 3 quarters · filed 2021-03-11 | $3.39M 10-K · filed 2021-03-11 | ||
| 2020-09-30 | $1.47M 10-Q · filed 2020-11-12 | $1.99M derived: sum of 2 quarters · filed 2020-11-12 | $2.36M derived: sum of 3 quarters · filed 2020-11-12 | |||
| 2020-06-30 | $514.05K 10-Q · filed 2020-11-12 | $882.19K derived: sum of 2 quarters · filed 2020-11-12 | ||||
| 2020-03-31 | $368.13K 10-Q · filed 2020-11-12 | |||||
| 2019-12-31 | $313.00K 10-K · filed 2021-03-11 | $943.00K 10-K · filed 2020-03-20 | ||||
| 2019-09-30 | $116.64K 10-Q · filed 2020-11-12 | $96.00K 10-Q · filed 2019-10-31 | $196.60K derived: sum of 2 quarters · filed 2020-11-12 | $250.98K derived: sum of 3 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $79.96K 10-Q · filed 2020-11-12 | $101.00K 10-Q · filed 2019-08-07 | $134.34K derived: sum of 2 quarters · filed 2020-11-12 | |||
| 2019-03-31 | $54.38K 10-Q · filed 2020-11-12 | $780.00K 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | $3.43M 10-K · filed 2020-03-20 | |||||
| 2018-09-30 | $904.00K 10-Q · filed 2019-10-31 | $1.83M derived: sum of 2 quarters · filed 2019-10-31 | $2.65M derived: sum of 3 quarters · filed 2019-10-31 | |||
| 2018-06-30 | $922.00K 10-Q · filed 2019-10-31 | $1.74M derived: sum of 2 quarters · filed 2019-10-31 | ||||
| 2018-03-31 | $821.00K 10-Q · filed 2019-10-31 | |||||
| 2017-12-31 | $3.23M 10-K · filed 2019-03-13 | |||||
| 2016-12-31 | $3.34M 10-K · filed 2019-03-13 | |||||
| 2015-12-31 | $2.16M 10-K · filed 2018-03-14 | |||||
| 2014-12-31 | $459.00K 10-K · filed 2017-03-16 | |||||
| 2013-12-31 | $155.00K 10-K · filed 2016-03-14 | |||||
| 2012-12-31 | $110.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |